Ignite Creation Date:
2025-12-24 @ 9:21 PM
Ignite Modification Date:
2025-12-27 @ 12:33 AM
Study NCT ID:
NCT05132504
Status:
RECRUITING
Last Update Posted:
2025-07-18
First Post:
2021-10-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
Sponsor:
Baylor College of Medicine
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-08-31
Start Date Type:
ACTUAL
Primary Completion Date:
2027-05-21
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-05-21
Completion Date Type:
ESTIMATED
First Submit Date:
2021-10-27
First Submit QC Date:
None
Study First Post Date:
2021-11-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-17
Last Update Post Date:
2025-07-18
Last Update Post Date Type:
ACTUAL